Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Email

Swamy Tripurani, Ph.D.

Program Director
SBIR Development Center
National Cancer Institute
swamy.tripurani@nih.gov

Dr. Swamy Tripurani joined the Small Business Innovation Research (SBIR) Development Center at the National Cancer Institute in January 2023. He serves as a Program Director, managing a portfolio of small businesses that develop novel diagnostics, devices, and targeted therapeutics (Biologics and small molecules) for cancer detection, diagnosis, and treatment. He is also involved in the CARE (Connecting Awardees with Regulatory Experts) program, which fosters interactions between NCI-funded small businesses and the Food and Drug Administration (FDA).   

 

Before joining NCI, Dr. Tripurani worked at the FDA for eight years as a research and regulatory review scientist. At the FDA, he reviewed Chemistry Manufacturing and Controls (CMC) attributes in drug applications and non-clinical studies in tobacco product applications. He also developed and executed multiple research projects focused on understanding mechanisms behind adverse toxicities associated with FDA-approved cancer therapies, for which he received numerous honor awards. Dr. Tripurani received his Ph.D. in Genetics and Developmental Biology from West Virginia University and completed his postdoctoral research training focused on reproductive disorders and cancer development at Baylor College of Medicine. He also worked as a clinical research associate in the Department of Investigational Cancer Therapeutics at MD Anderson Cancer Center.

Email